Tiny Matters [BONUS] Antarctic dinosaurs, blood restriction therapy, and an HIV prevention breakthrough: Tiny Show and Tell Us #46
May 6, 2026
Steven Ray Morris, podcast producer and dinosaur enthusiast behind See Jurassic Right, presents a chilly trip through Antarctic dinosaurs and how polar fossils reshape dinosaur stories. The conversation also covers a twice‑yearly injectable HIV prevention drug, Lenacapavir, and a primer on blood flow restriction therapy for rehab and strength rebuilding.
AI Snips
Chapters
Transcript
Episode notes
Twice Yearly HIV Prevention Targets The Capsid
- Lenacapavir is a twice-yearly injectable antiretroviral that targets the HIV capsid rather than enzymes like reverse transcriptase.
- Gilead converted a highly stable compound into a subcutaneous slow-release formulation (GS6207 → lenacapavir) to achieve six-month dosing.
Capsid Targeting Blocks Multiple Steps Of Infection
- Targeting the viral capsid blocks multiple stages: assembly, stability, uncoating, and cell entry, reducing viral replication opportunities.
- Capsid targeting was attractive because some capsid mutations already impair infectivity and monkey proteins block uncoating.
Long Acting PrEP Reduces Adherence But Needs Combination For Treatment
- Monotherapy risks resistance because HIV mutates rapidly, so lenacapavir as treatment must be combined with other antiretrovirals.
- As PrEP a long-acting option reduces adherence challenges compared with daily pills or monthly shots.